Tirzepatide from Hilma Biocare contains an active compound that acts as a dual agonist of both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. This unique combination of mechanisms allows for a more comprehensive approach to managing glucose levels and body weight, a key factor in modern hormone therapy and metabolic health control.
Tirzepatide itself is an analogue of the human hormone GIP, which stimulates insulin release. The active half-life of the drug is up to five days. Although the compound is not a direct anabolic steroid, its impact on body composition and metabolism draws interest in communities discussing sports pharmacology and body optimization.
Reviews
There are no reviews yet.